Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...
Cell And Gene Therapies In Rare Disorders Market To Skyrocket Across The 7MM During The Forecast Period (2025–2034) | Delveinsight
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
ophthalmologyadvisor21h
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Novel PET tracer reveals potential for recovery in spinal cord injuries
A novel PET technique that visualizes spinal cord injuries provides critical information about which patients may be able to ...
The American Journal of Managed Care20h
Redefining Functional Measures in SMA: Insights From Clinical Research
The evolution of functional assessments for spinal muscular atrophy (SMA) highlights the challenges of adapting pediatric ...
Too Old to Operate19h
Shorter MPFI Reliably Evaluates Chronic Pain
A shorter MPFI designed specifically for patients with chronic pain proved generally valid and reliable on a group level, according to a recent study.